

AD _____

Award Number: DAMD17-00-1-0130

TITLE: A Molecular Model for Repression of BRCA-1 Transcription
by the Aryl Hydrocarbon Receptor

PRINCIPAL INVESTIGATOR: Donato F. Romagnolo, Ph.D.

CONTRACTING ORGANIZATION: University of Arizona
Tucson, Arizona 85722-3308

REPORT DATE: July 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050105 013

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY
(Leave blank)**2. REPORT DATE**
July 2004**3. REPORT TYPE AND DATES COVERED**
Final (1 Jul 00 - 30 Jun 04)**4. TITLE AND SUBTITLE**A Molecular Model for Repression of BRCA-1 Transcription
by the Aryl Hydrocarbon Receptor**5. FUNDING NUMBERS**

DAMD17-00-1-0130

6. AUTHOR(S)

Donato F. Romagnolo, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)University of Arizona
Tucson, Arizona 85722-3308

E-Mail: donato@u.arizona.edu

**8. PERFORMING ORGANIZATION
REPORT NUMBER****9. SPONSORING / MONITORING
AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

The purpose of this project is to investigate whether or not regulation of expression of the BRCA-1 gene in breast epithelial cells exposed to polycyclic aromatic hydrocarbons (PAHs) is mediated by the aryl hydrocarbon receptor (AhR). The scope of the project is to examine whether or not the AhR complexed with the AhR-nuclear transporter (ARNT) protein, binds to several xenobiotic responsive elements (XRE) strategically located at -539 bp (CCGTGGAA=Cyp1A1-like) and +20base pairs (bp) (GCGTG=XRE-1) from the transcription start site on exon-1A. Two additional XREs (GCGTG) have been localized at -107 bp in the intervening sequence upstream (XRE-2) and +218 bp (XRE-3) into exon-1B. Findings of the experiments conducted during the last period include: 1) Completed testing of mutation constructs for XRE2 and investigated the effects of antagonists of the AhR and ER α on regulation of BRCA-1 transcription by estrogen and the dioxin-like compound TCDD in breast cancer MCF-7 cells. 2) Characterized the mechanism of interaction between the ER α and the AhR at the XRE-2 by chromatin immunoprecipitation assay (ChIP).

14. SUBJECT TERMS

BRCA-1, Benzo[a]pyrene, aromatic hydrocarbon receptor

15. NUMBER OF PAGES

13

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	10
Reportable Outcomes.....	11
Conclusions.....	12
References.....	13
Appendices.....	

Introduction

The subject of the research is to investigate whether or not exposure to polycyclic aromatic hydrocarbons (PAHs) may be a risk factor in the onset of mammary neoplasia by altering transcription of the tumor suppressor gene, BRCA-1. The purpose of this project is to investigate whether or not changes in the expression of the BRCA-1 gene in breast epithelial cells induced by PAHs is mediated by the aryl hydrocarbon receptor (AhR). The scope of the project is to examine whether or not the AhR complexed with the AhR-nuclear transporter (ARNT) protein, binds to several xenobiotic responsive elements (XRE) strategically located at -539 bp (CCGTGGAA=Cyp1A1-like) and +20base pairs (bp) (GCGTG=XRE-1) from the transcription start site on exon-1A. Two additional XREs (GCGTG) have been localized at -107 bp in the intervening sequence upstream (XRE-2) and +218 bp (XRE-3) into exon-1B. Results presented in this progress report dealt with the role of the AhR in regulation of BRCA-1 transcription by the ER α and the cross-talk between the two receptors following stimulation of BRCA-1 transcription with estrogen.

Body

Synopsis

The tasks of the last year focused on completing testing of mutation constructs for XRE2 and investigated the effects of antagonists of the AhR and ER α on regulation of BRCA-1 transcription by estrogen and the dioxin-like compound TCDD in breast cancer MCF-7 cells. In addition, we wished to characterize the mechanism of interaction between the ER α and the AhR at the XRE-2 by chromatin immunoprecipitation assay (ChIP).

Mutation construct for XRE-2 and effects of the AhR-ligand TCDD

The results depicted in [Figure 1](#) confirmed that estrogen stimulated transcription from the BRCA-1 promoter, whereas this effect was antagonized by the AhR-ligand TCDD. Mutation of the XRE-2 reduced basal activity and prevented the stimulation previously seen with estrogen ([Figure 2](#)). These results are very important because they indicate that 1) ligands of the AhR prevent estrogen stimulation of BRCA-1 transcription, and 2) the presence of the XRE-2 is required for estrogen activation of BRCA-1 transcription. The latter result establishes a role for the XRE-2 and the AhR in regulation of BRCA-1 transcription. This conclusion was corroborated by the results presented in [Figure 3](#). These data suggested that cotreatment of MCF-7 cells transfected with the BRCA-1 promoter construct pGL3BRCA-1 with estrogen plus the AhR antagonist alpha-naphthoflavone (ANF) prevented estrogen stimulation of BRCA-1 transcription. Again, these results indicate that the AhR contributes to estrogen activation of BRCA-1 transcription. We then tested the effects of a pure antagonist (3'-methoxy-4'-nitroflavone, 3M4NF). The results presented in [Figure 4](#) strongly confirm the role of the AhR in the estrogen upregulation of BRCA-1 transcription since cotreatment with 3M4NF abrogated the increase in promoter activity caused by estrogen.

Chromatin immunoprecipitation assay

The implications of these results are significant because they establish a role for ligands of the AhR and ER α . In detail, our results suggest that the effects of estrogen on BRCA-1 transcription will depend on whether or not ligands of the AhR are present in the nuclear environment. To test this hypothesis we performed a series of experiments using the chromatin immunoprecipitation assay. This assay through a combination of immunoprecipitation with specific antibodies and PCR amplification allows examination of the occupancy of segments of promoter DNA by specific factors. In detail, we wished to examine the effects of TCDD on recruitment of the ER α at the XRE-2. The results of [Figure 4](#) indicated that the treatment with TCDD stimulated the recruitment of the ER α as documented by the appearance of a band following PCR amplification of the DNA segment comprised by the oligonucleotides Ch-XRE-F and Ch-XRE-R ([Figure 5](#)). These results suggest that the presence of the AhR ligand TCDD facilitates the recruitment of the ER α and the XRE-2. In contrast, cotreatment with TCDD plus

estrogen causes a loss of the ER α from this site and the coincident loss of transcription activity.




Figure 1. Cotreatment with TCDD represses estrogen-induced BRCA-1 transcription in breast cancer MCF-7 cells.




Figure 2. Mutation of XRE-2 prevents estrogen activation of BRCA-1 transcription.




Figure 3. The AhR antagonist ANF prevents estrogen stimulation of BRCA-1 transcription.





Figure 4. the pure antagonist 3M4NF antagonizes BRCA-1 transcription induced by estrogen.

A



B




Figure 5. Chromatin immunoprecipitation assay of ER α at the XRE-2. Bands represent PCR amplification products following crosslinking and immunoprecipitation with an antibody for the ER α . The PCR products were generated using oligonucleotides flanking the A) XRE-2 or B) an Sp-1/AP-1 site known to be targeted by the ER α (positive control).

Key research Accomplishments

- Completed analysis of mutation construct for XRE2 and the role of antagonists of the AhR in regulation of estrogen stimulation of BRCA-1 transcription.
- Obtained new evidence by ChIP assay of cross-talk between AhR ligands and estrogen in recruitment of the ER α at the BRCA-1 promoter.

Reportable Outcomes

1. Brandon D. Jeffy. Dissertation for a Ph.D. in Cancer Biology, The University of Arizona, December 2004.
2. Jennifer Ku. Data acquired through the execution of this project is being used for the preparation of a Ph.D. dissertation for the Cancer Biology. The support of the US Army Medical Research and Materiel Command has been acknowledged in the Acknowledgment section of these reports:
 1. Abstracts presented at the 94th Meetings of the AACR, 842:4230 Breast Cancer and Environmental Mutagens Conference, Environmental Mutagen Society, Research Triangle Park, NC, September 22-25, 2001.
 2. Posters presented at the Arizona Cancer and Southwest Environmental Health Sciences Centers, The University of Arizona, Tucson, AZ.
 3. Preclinical Models of Breast Cancer Research Conference. 24th Congress of the International Association for Breast Cancer Research, UC Davis, Sacramento.

Conclusions

Summary

Based on the data obtained through the completion of the experiments outlined in the Body section of this report, we can conclude that exposure to ligands of the aromatic hydrocarbon receptors regulates transcription of the BRCA-1 gene, likely through XREs comprised in the BRCA-1 promoter. The mechanism being proposed is that through binding to AhR-binding domains, the AhR regulates the expression of BRCA-1. In detail, we propose that the XRE-2 selected as a prototype of other XREs found in the BRCA-1 gene, is required for estrogen activation of BRCA-1 transcription.

Importance and Implications

The findings of this Report confirm the original assumption that AhR-ligands may contribute to basal and estrogen regulation of BRCA-1 expression. These conclusions have been confirmed with the results of the transfections with mutation constructs for XRE-2. Results obtained with ChIP assay presented with this report have clarified that the ER α is recruited at the XRE-2 may contribute to formation of a transcription complex with the AhR.

Relevant References

1. Romagnolo, D., Annab, L.A., Lyon, T.T., Risinger, J.I., Terry, L.A., Barrett, J.C., and Afshari, C.A. Estrogen upregulation of expression of BRCA-1 with no effect on localization. *Mol. Carcinogen.*, 22, 102-109, 1998.
2. Jeffy, B.D., Schultz, E.U., Selmin, O., Gudas, J.M., Bowden, G.T., and Romagnolo, D. Inhibition of BRCA-1 expression by benzo[a]pyrene and its diol epoxide. *Mol. Carcinogen.*, 26, 100-118, 1999.
3. Jeffy, B.D., Chen, E.J., Gudas, J.M., and Romagnolo, D.F. Disruption of cell cycle kinetics by benzo[a]pyrene: Inverse expression patterns of BRCA-1 and p53 in MCF-7 cells arrested in S and G2. *Neoplasia*, 2, 460-470, 2000.
4. Brandon D. Jeffy, Ryan B. Chirnomas, Eddy J. Chen, Jean M. Gudas, and Donato F. Romagnolo. Activation of the Aromatic Hydrocarbon Receptor Pathway Is Not Sufficient for Transcriptional Repression of BRCA-1: Requirements for Metabolism of Benzo[a]pyrene to 7*r*,8*t*-Dihydroxy-9*t*,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. *Cancer Res* 2002 62: 113-121.
5. Brandon D. Jeffy, Ryan B. Chirnomas, and Donato F. Romagnolo. Epigenetics of breast cancer: polycyclic aromatic hydrocarbons as risk factors. *Environ. Mol. Mutagenesis*, Vol 39, 2-3, 2002.